Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UltraCAR-T, AdenoVerse, cash runway, and clinical milestones—Precigen’s SEC documents pack dense science and finance into hundreds of pages. Finding the R&D spend that fuels its gene-therapy platforms or tracing when executives sell shares can feel overwhelming. Stock Titan’s AI turns that complexity into clarity, offering Precigen SEC filings explained simply and in context.
Whether you need the latest Precigen quarterly earnings report 10-Q filing or an alert on Precigen Form 4 insider transactions real-time, our platform surfaces the data as soon as it hits EDGAR. Key features:
- AI-powered summaries that reduce a 300-page 10-K to bullet-point insights—Precigen annual report 10-K simplified
- One-click access to Precigen insider trading Form 4 transactions and executive stock patterns
- Contextual flags for 8-K trial updates—Precigen 8-K material events explained
- Real-time monitoring of cash burn, collaboration revenue, and segment results across filings
Use cases are practical: compare quarter-over-quarter R&D trends, track Precigen proxy statement executive compensation, or run a Precigen earnings report filing analysis before your next investment committee meeting. By understanding Precigen SEC documents with AI, investors quickly see how UltraVector manufacturing efficiency or AdenoVerse vaccine data affect valuation. No more page flipping—just the biotech insights that matter, delivered the moment PGEN files.
Precigen Chief Commercial Officer Phil Tennant received a significant equity compensation award on June 26, 2025, consisting of 125,000 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of Precigen common stock upon vesting.
The RSUs follow a specific vesting schedule: 50% will vest on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years. The grant was awarded at $0 exercise price, as is typical for RSU compensation.
This Form 4 filing, submitted by Tennant's attorney-in-fact Donald P. Lehr, reflects standard executive compensation practices and aligns the executive's interests with long-term shareholder value through the extended vesting period.
Precigen COO Rutul R. Shah received a significant equity award of 180,000 Restricted Stock Units (RSUs) on June 26, 2025. The RSUs represent the right to receive an equivalent number of Precigen common stock shares upon vesting.
The vesting schedule is structured as follows:
- 50% of RSUs vest on May 23, 2026
- Remaining 50% vest in equal monthly installments over the following three years
This Form 4 filing, executed by Donald P. Lehr as attorney-in-fact on Shah's behalf, indicates a long-term retention strategy for the Chief Operating Officer. The RSUs were granted at $0 cost to the executive, representing a significant potential value tied to future company performance and share price appreciation.
Donald P. Lehr, Chief Legal Officer of Precigen (PGEN), reported receiving 125,000 Restricted Stock Units (RSUs) on June 26, 2025. Each RSU represents a contingent right to receive one share of Precigen common stock.
The RSUs follow a specific vesting schedule: 50% will vest on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years. The RSUs were granted at no cost ($0) to the executive.
This equity compensation grant aligns the legal officer's interests with shareholders through long-term vesting requirements. The transaction was reported via Form 4 within the required reporting timeframe, with the filing made on June 28, 2025.
Helen Sabzevari, President, CEO, and Director of Precigen, received a significant equity award of 500,000 Restricted Stock Units (RSUs) on June 26, 2025. This represents a substantial insider grant that aligns executive interests with shareholder value.
Key details of the RSU grant:
- Each RSU converts to one share of Precigen common stock
- Vesting schedule: 50% vests on May 23, 2026, with remaining vesting in equal monthly installments over three years
- Grant price: $0 (typical for RSU awards)
- Ownership form: Direct
This Form 4 filing indicates continued commitment to executive retention and long-term performance alignment through equity-based compensation. The extended vesting schedule suggests a focus on long-term value creation and executive retention.
Precigen CFO Harry Thomasian Jr. received a significant equity award in the form of 175,000 Restricted Stock Units (RSUs) on June 26, 2025. The RSUs represent the right to receive an equivalent number of Precigen common stock shares.
The vesting schedule for these RSUs is structured as follows:
- 50% vesting on May 23, 2026 (initial cliff vesting)
- Remaining 50% vesting in equal monthly installments over the subsequent three years
This Form 4 filing, signed by Donald P. Lehr as attorney-in-fact, indicates a long-term retention strategy for the CFO position. The RSUs were granted at no cost ($0) to the executive, representing a significant equity incentive aligned with shareholder interests. The award demonstrates Precigen's commitment to executive compensation through equity-based incentives.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
What is the primary focus of Precigen Inc?
How does Precigen generate revenue?
What distinguishes Precigen's technological platforms?
Which therapeutic areas does Precigen target?
How is Precigen positioned in the competitive biotechnology landscape?
What role do partnerships play in Precigen's business model?
